Clinical Trial

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)

Study acronym: MARVEL-PIC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
A prospective, open, randomised implementation study in paediatric cancer patients. The study aims to determine whether a personalised approach will result in an overall reduction in clinically relevant adverse drug reactions (ADRs) and to evaluate the economic and quality of life impacts. Participants will be randomised to receive personalised guided prescribing of supportive care therapy (study arm) or standard of care (control arm) for a period of 12 weeks. The follow up period includes prospective patient reporting of symptoms and quality of life through electronically delivered surveys, for a maximum of 12 months.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-07-30
notable Enrollment reduced: 880 -> 441 participants 2026-07-30
notable Primary completion moved earlier: 2026-08 -> 2026-06-30 2026-07-30
Trial Details
NCT Number NCT05667766
Lead Sponsor Murdoch Childrens Research Institute
Conditions Neoplasms, Bone Marrow Transplantation
Enrollment 441 participants
Start Date 2023-03-22
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29